Antonio Giordano: First-in-Human Study of CDK2/4/6 Inhibitor PF-06873600 in Breast Cancer
Antonio Giordano, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post on by Dana-Farber’s Breast Oncology Center, on X, adding:
“One of the first attempts to crack cell cycle resistance in HR+ breast cancer by adding CDK2 coverage. Many more clinical trials are ongoing with selective CDK2 inhibitors-recycle cell cycle”
Quoting Dana-Farber’s Breast Oncology Center‘s post:
“Check out this First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.”
Title: First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Authors: Timothy A Yap, Jonathan W Goldman, Shaveta Vinayak, Antoaneta Tomova, Erika Hamilton, Yoichi Naito, Antonio Giordano, Igor Bondarenko, Toshinari Yamashita, Li Zhou, Allison Moreau, Heather Neumann, Jessica Tougias, Feng Liu, Jennifer Park, Maria Delioukina, Komal Jhaveri
More posts featuring Antonio Giordano on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023